title: Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma.
abstract: OBJECTIVE
  To describe efficacy and safety of stereotactic body radiation therapy (SBRT) for the treatment of inoperable hepatocellular carcinoma.
  
  
  METHODS
  The records of 77 consecutive patients treated with SBRT for 97 liver-confined HCC were reviewed. A total dose of 45Gy in 3 fractions was prescribed to the 80% isodose line. Local control (LC), overall survival (OS), progression-free survival (PFS) and toxicity were studied.
  
  
  RESULTS
  The median follow-up was 12months. The median tumor diameter was 2.4cm. The LC rate was 99% at 1 and 2years. The 1 and 2-year OS were 81.8% and 56.6% respectively. The median time to progression was 9months (0-38). The rate of hepatic toxicity was 7.7% [1.6-13.7], 14.9% [5.7-23.2] and 23.1% [9.9-34.3] at 6months, 1year and 2years respectively. In multivariate analysis, female gender (HR 7.87 [3.14-19.69]), a BCLC B-C stage (HR 3.71 [1.41-9.76]), a sum of all lesion diameters ⩾2cm (HR 7.48 [2.09-26.83]) and a previous treatment (HR 0.10 [0.01-0.79]) were independent prognostic factors of overall survival.
  
  
  CONCLUSIONS
  SBRT allows high local control for inoperable hepatocellular carcinomas. It should be considered when an ablative treatment is indicated in Child A patients.
authors.affiliation: Department of Radiotherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.
authors.forename: Andres
authors.initials: A
authors.lastname: Huertas
authors.affiliation: Department of Radiotherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Baumann
authors.affiliation: Department of Radiotherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.
authors.forename: Fleur
authors.initials: F
authors.lastname: Saunier-Kubs
authors.affiliation: Department of Biostatistics and Data Management, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.
authors.forename: Julia
authors.initials: J
authors.lastname: Salleron
authors.affiliation: Department of Radiology, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Oldrini
authors.affiliation: Department of Radiology, CHU de Nancy, Vandoeuvre-Lès-Nancy, France.
authors.forename: Valérie
authors.initials: V
authors.lastname: Croisé-Laurent
authors.affiliation: Department of Hepatogastroenterology, CHU de Nancy, Vandoeuvre-Lès-Nancy, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Barraud
authors.affiliation: Department of Digestive, Hepato-biliary and Endocrine Surgery, CHU de Nancy, Vandoeuvre-Lès-Nancy, France.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Ayav
authors.affiliation: Department of Hepatogastroenterology, CHU de Nancy, Vandoeuvre-Lès-Nancy, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Bronowicki
authors.affiliation: Department of Radiotherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France. Electronic address: d.peiffert@nancy.unicancer.fr.
authors.forename: Didier
authors.initials: D
authors.lastname: Peiffert
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016634:Radiosurgery
keywords: AFP; Ablative treatment; Liver tumor; Local control; RILD; Radiofrequency ablation